Randomized trial · people

Teriparatide plus denosumab: 12.9% spine BMD gain at 24 months

Checked against the paper Randomized trialPublished by PepVault

The takeaway

Over 2 years, adding denosumab to teriparatide gave larger spine and hip bone density gains than either drug alone, with most of the extra gain arriving in the first year.

Kind
Randomized trial
Studied in
People
Number studied
94
Published
2014
Journal
J Clin Endocrinol Metab

What they tested

The team tested whether 24 months of teriparatide and denosumab given together would raise hip and spine bone density more than either drug on its own.

How the study was done

A randomized controlled trial in 94 postmenopausal women with osteoporosis, planned in advance as a continuation of the original DATA trial. Women got teriparatide (the 20 μg daily arm), denosumab (the 60 mg every 6 months arm), or both for 24 months.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking teriparatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

At 24 months, lumbar spine BMD (bone mineral density, a scan-based measure of bone strength) rose 12.9% with the combination, compared with 9.5% on teriparatide alone and 8.3% on denosumab alone. Femoral neck BMD rose 6.8% with both drugs versus 2.8% and 4.1%, and total hip BMD rose 6.3% versus 2.0% and 3.2%. Spine and hip density kept climbing in all three groups during year 2, but the year 2 gains were similar across groups. Blood markers of bone turnover C-telopeptide and N-terminal propeptide of type 1 procollagen were suppressed to the same degree with denosumab alone and with the combination, while osteocalcin fell more with denosumab alone.

What it doesn’t show

This was a small trial that measured bone density and blood markers, not fractures, so it does not show whether the combination prevents more broken bones. It included only postmenopausal women with osteoporosis.

The paper

Leder et al. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab. 2014.

The compound

More studies on Teriparatide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking teriparatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo